Serum circulating free DNA of syncytin-1 as a novel molecular marker for early diagnosis of non-small-cell lung cancer

• Published in: Biomarkers in medicine Vol. 16; no. 18; pp. 1259 - 1268
• Main Authors: Zhuang, Xuewei, Qian, Jingrong, Xia, Xiyan, Wang, Yuanling, Wang, Hongchun, Jing, Liping, Zhang, Yanli, Zhang, Yong
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.12.2022
• Subjects: Biomarkers, Tumor - genetics; Carcinoma, Non-Small-Cell Lung - genetics; Cell-Free Nucleic Acids; circulating free DNA; DNA; Early Detection of Cancer; early diagnosis; Humans; liquid biopsy; Lung Neoplasms - genetics; molecular marker; non-small-cell lung cancer; smoking history; syncytin-1; early diagnosis; syncytin-1; circulating free DNA; molecular marker; smoking history; liquid biopsy; non-small-cell lung cancer
• ISSN: 1752-0363; 1752-0371
• DOI: 10.2217/bmm-2022-0499

Liquid biopsy has been receiving attention as an emerging detection technology in the clinical application of non-small-cell lung cancer (NSCLC). We quantified serum circulating free DNA (cfDNA) of syncytin-1 in 126 patients and 106 controls, analyzed the correlation of level with pathological parameters and explored diagnostic utility. The cfDNA of syncytin-1 levels in NSCLC patients were higher than healthy controls (p < 0.0001). These levels were associated with smoking history (p = 0.0393). The area under the curve of cfDNA of syncytin-1 was 0.802, and combination of cfDNA of syncytin-1/cytokeratin 19 fragment antigen 21-1/carcinoembryonic antigen markers improved diagnostic efficiency. The cfDNA of syncytin-1 was detected in NSCLC patients and can be used as a novel molecular marker for early diagnosis.